Are We Nearing the End of the Debate Regarding Steroid Efficacy and Safety in IgAN?
Speakers: Jürgen Floege, MD, Head of the Division, Nephrology and ImmunologyJai Radhakrishnan, MD, MS, Professor of Medicine
Duration: 60 minutes
Presented on: February 24, 2023
Jürgen Floege, MD
Jürgen Floege, MD
Head of the Division, Nephrology and ImmunologyJürgen Floege, MD, is head of the Division of Nephrology and Immunology at the University of Aachen, Germany since 1999. Dr. Floege is a former executive council member of the International Society of Nephrology (ISN), the European Renal Association (ERA-EDTA), and currently coordinates the KDIGO glomerular disease management guidelines. His research interests encompass both basic research like studies underlying progression of renal disease in particular renal fibrosis as well as clinical research in immune-mediated renal disease, bone and mineral disorders (CKD-MBD), and cardiovascular disease in uremic patients. Furthermore, Dr. Floege is a Distinguished Fellow of the ERA-EDTA and recipient of the 2018 ERA-EDTA Award for Outstanding Clinical Contributions to Nephrology.
Jai Radhakrishnan, MD, MS
Jai Radhakrishnan, MD, MS
Professor of MedicineDr. Radhakrishnan is Professor of Medicine at Columbia University Medical Center and the Clinical Director of the Nephrology Division. His clinical and research interests are in glomerular diseases. He is an associate editor of Kidney International and founding editor/editor-in-chief of Kidney International Reports. He has served on educational committees with the American Society of Nephrology and the International Society of Nephrology and is a global education ambassador for the ISN. He has lectured extensively internationally and has received numerous awards for his educational and patient care-related achievements.
CME InformationAre We Nearing the End of the Debate Regarding Steroid Efficacy and Safety in IgAN?This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with Kidney Disease: Improving Global Outcomes (KDIGO).
ACKNOWLEDGEMENTThis activity is supported by an educational grant from Calliditas.
DATE OF LIVE ACTIVITYThis activity was released on February 24, 2023 and is valid for 12 months. Requests for credit must be made no later than February 24, 2024.
TARGET AUDIENCEThe educational design of this activity addresses the needs of nephrologists, internists, PCPs, dialysis staff and medical directors, pharmacists, and aligned HCPs.
STATEMENT OF NEED/PROGRAM OVERVIEWIf left untreated, immunoglobulin‐A nephropathy (IgAN) can lead to kidney failure, dialysis, and transplantation. The current standard of care, RAS inhibition, has limited efficacy, while recently updated KDIGO guidelines for the management of IgAN highlight the risks associated with systemic corticosteroids and immunosuppressants. An enhanced understanding of the underlying pathophysiology of IgAN could lead to improved options in reducing the first step in the inflammatory process.
Join a panel of expert nephrologists to review the changing standards of care for IgAN and explore the mechanisms of action, safety, and efficacy of new therapeutic options. Panelists will discuss the key roles of Peyer’s patches in the inflammatory process in glomerular mesangium, which can be reduced with delayed‐release budesonide. The activity will also review new and emerging surrogate endpoints for kidney-disease clinical trials and help clinicians understand how to utilize trials to evaluate patient response to therapy.
EDUCATIONAL OBJECTIVESAfter completing this activity, the participant should be better able to:
- Identify the manifestations and diagnostic process for IgAN
- Recognize patients who are at high risk of progression despite RAS inhibition
- Explain the role of the ileal lymphoid tissue, specifically Peyer’s patches as a major source of IgA responsible for IgAN, and describe the implications for treatment with steroids
- Summarize the safety and efficacy data of the delayed-release budesonide formulation in proteinuria reduction and kidney function
PHYSICIAN ACCREDITATION STATEMENTThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.
PHYSICIAN CREDIT DESIGNATIONGlobal Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ESTIMATED TIME TO COMPLETEThis activity should take approximately 1 hour to complete.
INSTRUCTIONS TO RECEIVE CREDITIn order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.
HARDWARE/SOFTWARE REQUIREMENTSParticipants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.
FEE INFORMATION & REFUND/CANCELLATION POLICYThere is no fee for this educational activity.
DISCLOSURES OF RELEVANT FINANCIAL RELATIONSHIPSGlobal Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.
All relevant financial relationships have been mitigated.
The faculty have the following relevant financial relationships with ineligible companies:
Name of Faculty or Presenter Reported Financial Relationship Jürgen Floege, MD
Professor of Medicine
Division of Nephrology and Rheumatology
RWTH Aachen University Hospital, Germany
Consulting Fee (e.g., Advisory Board): AstraZeneca, Bayer, Boehringer, Calliditas, Novartis, Omeros, Travere, Vifor
Honoraria: AstraZeneca, Bayer, Boehringer, Calliditas, Novartis, Omeros, Travere, Vifor
Speakers' Bureau: AstraZeneca, Bayer, Boehringer, Calliditas, Novartis, Omeros, Travere, Vifor Data Safety Monitoring Board Member: NovoNordisk, Visterra
Jai Radhakrishnan, MD, MS
Professor of Medicine, Columbia University Medical Center
Clinical Director, Division of Nephrology
Columbia University Vagelos College of Physicians and Surgeons
Consulting Fee (e.g., Advisory Board): Angion Biomedica, ANI Pharmaceuticals, Aurinia Pharmaceuticals, Equillium Bio, GlaxoSmithKline, Mallinckrodt, Sanofi Genzyme, Travere
Contracted Research: Goldfinch Bio, Travere, Vertex pharmaceuticals
The planners and managers at Global Education Group have no relevant financial relationships to disclose.
The planners and managers at PlatformQ Health Education have no relevant financial relationships to disclose.
DISCLOSURE OF UNLABELED USEThis educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMERParticipants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities
Physician Accreditation Support:For information about the physician accreditation of this program, please contact Global at 303-395-1782 or firstname.lastname@example.org.>.
Technical Support:For any technical issues or issues with your CME Certificate, please contact ClinicalSeriesLive at 877-394-1306 or at Support@ClinicalSeriesLive.com.